China FDA changes will speed up approval process, says CRO

By Flora Southey

- Last updated on GMT

Four new draft policies were released May 11. (Image: iStock/Golden_Brown)
Four new draft policies were released May 11. (Image: iStock/Golden_Brown)

Related tags Clinical trial

Proposed changes to drug, medical device and clinical testing regulations provide stimulus for conducting trials in China, says CRO George Clinical.

The contract research organisation’s (CRO) managing director, Philip Gregory, said the China Food and Drug Administration’s (CFDA) four new draft policies​ (in Chinese), released May 11, herald an exciting new era for drug and device development.

“If implemented in full, these proposed changes will standardise regulatory requirements, allow for greater use of foreign data broadening eligibility of sites to conduct trials, provide greater transparency of the ethics processes, and ultimately shorten approval timelines,” ​he said.

According to the China-based director, the policies support investigators and clinical testing organisations to carry out clinical trials, improve the clinical trial review process, accept overseas clinical trial data, and support exploratory clinical research, which, if approved, will make the CFDA regulations comparable with other major global players.

The proposed changes show a “proactive response by a regulatory body keen to improve the overall drug development process and make new medicines available faster for the Chinese population,” ​he said.

The draft policies – open for public comment until June 10 – highlight Chinese regulators’ continued commitment to improving access to medicines.

The CFDA released proposed changes​ to drug trial and API importation laws on March 17 to shorten clinical trials and approval times to meet “public demand for new drugs.” 

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

Related suppliers

Follow us

Products

View more

Webinars